Equities

Fortress Biotech Inc

Fortress Biotech Inc

Actions
  • Price (EUR)1.93
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-57.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 10 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments81178306
Total Receivables, Net152824
Total Inventory10149.86
Prepaid expenses119.667.07
Other current assets, total------
Total current assets117230346
Property, plant & equipment, net233334
Goodwill, net------
Intangibles, net202713
Long term investments----0
Note receivable - long term------
Other long term assets4.280.971.20
Total assets168294397
LIABILITIES
Accounts payable355747
Accrued expenses232325
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.007.244.51
Other current liabilities, total5.82213.77
Total current liabilities85128101
Total long term debt619347
Total debt6410051
Deferred income tax------
Minority interest(21)8.30117
Other liabilities, total202323
Total liabilities145253288
SHAREHOLDERS EQUITY
Common stock0.020.110.10
Additional paid-in capital717676656
Retained earnings (accumulated deficit)(695)(634)(547)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2342109
Total liabilities & shareholders' equity168294397
Total common shares outstanding157.376.76
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.